Back to top

Is Gilead Sciences a Great Stock for Value Investors?

Read MoreHide Full Article

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Gilead Sciences Inc. (GILD - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Gilead Sciences has a trailing twelve months PE ratio of 9.3, as you can see in the chart below:

This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 20.1x. If we focus on the long-term PE trend, Gilead Sciences’ current PE level puts it below its midpoint over the past five years, with the number having risen rapidly over the past few months.

Further, the stock’s PE also compares favorably with the broader industry’s trailing twelve months PE ratio, which stands at 37.6. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.

We should also point out that Gilead Sciences has a forward PE ratio (price relative to this year’s earnings) of just 12.8, which is tad higher than the current level. So it is fair to expect an increase in the company’s share price in the near term.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Gilead Sciences has a P/S ratio of about 3.8. This is marginally above the S&P 500 average, which comes in at 3.3x right now. However, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.

If anything, GILD is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, Gilead Sciences currently has a Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes Gilead Sciences a solid choice for value investors.

What About the Stock Overall?

Though Gilead Sciences might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of F and a Momentum Score of D. This gives GILD a Zacks VGM score — or its overarching fundamental grade — of C. (You can read more about the Zacks Style Scores  here >>)

Meanwhile, the company’s recent earnings estimates have been stable with no significant revisions in the current quarter and the full year estimate in the last two months.

This has had just a small impact on the consensus estimate though as the current quarter consensus estimate remained stable in the past two months, while the full year estimate has inched upper by 0.2%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Gilead Sciences, Inc. Price and Consensus

 

The stock has just a Zacks Rank #3 (Hold) and we are looking for in-line performance from the company in the near term.

Bottom Line

Gilead Sciences is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (among Bottom 36% of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past two years, the broader industry has clearly underperformed the market at large, as you can see below:

 

So, value investors might want to wait for estimates and analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.     

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.  

See the pot trades we're targeting>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Gilead Sciences, Inc. (GILD) - free report >>

More from Zacks Analyst Blog

You May Like